Market Cap : 10.15 B | Enterprise Value : 8.68 B | PE Ratio : 16.88 | PB Ratio : 2.35 |
---|
NAS:UTHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:UTHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, United Therapeutics's share price is $223.045. United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $37.40. Hence, United Therapeutics's PS Ratio for today is 5.96.
Warning Sign:
United Therapeutics Corp stock PS Ratio (=5.93) is close to 5-year high of 6.53
The historical rank and industry rank for United Therapeutics's PS Ratio or its related term are showing as below:
During the past 13 years, United Therapeutics's highest PS Ratio was 7.05. The lowest was 2.16. And the median was 3.70.
UTHR's PS Ratio is ranked better thanUnited Therapeutics's Revenue per Sharefor the three months ended in Jun. 2022 was $9.71. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $37.40.
Warning Sign:
United Therapeutics Corp revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of United Therapeutics was 7.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -1.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -1.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 9.90% per year.
During the past 13 years, United Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 260.90% per year. The lowest was -4.70% per year. And the median was 28.20% per year.
The historical data trend for United Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, United Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, United Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where United Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
United Therapeutics's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 223.045 | / | 37.4 | |
= | 5.96 |
United Therapeutics's Share Price of today is $223.045.
United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.40.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of United Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Benkowitz Michael | officer: President and COO | C/O UNITED THERAPEUTICS CORP 1040 SPRING STREET SILVER SPRING MD 20910 |
Maxwell Linda | director | 1040 SPRING STREET SILVER SPRING NC 27709 |
Thompson Tommy G | director | 7711 CARONDELET ST. LOUIS MO 63105 |
Mesa Nilda | director | C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910 |
Klein Katherine J | director | STEINBERG HALL-DIETRICH HALL 3620 LOCUST WALK PHILADELPHIA PA 19104 |
Giltner Richard | director | C/O UNITED THERAPEUTICS CORPORTION 1735 CONNECTICUT AVE. NW WASHINGTON DC 20009 |
Olian Judy D. | director | 2000 AVENUE OF THE STARS 12TH FL LOS ANGELES CA 90067 |
Edgemond James | officer: CFO and Treasurer | 1040 SPRING STREET SILVER SPRING MD 20910 |
Zaccardelli David | officer: EVP & Chief Operating Officer | 300 TRI STATE INTERNATIONAL SUITE 272 LINCOLNSHIRE IL 60069 |
Eli Lilly & Co | 10 percent owner | LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285 |
Ferrari John Maxim | officer: CFO & Treasurer | 1110 SPRING STREET SILVER SPRING MD 20910 |
Patusky Christopher | director | |
Hicks Henry Beecher Iii | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Gray R Paul | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Dwek Raymond | director |
From GuruFocus
Other Sources
By Zacks 2021-11-04
By Zacks 2021-12-03
By Zacks 2021-08-05
By Fool 2021-08-04
By tipranks.com 2022-02-11
By Zacks 2021-06-04
By Zacks 2022-02-24
By Zacks 2022-02-16
By Zacks 2022-02-25
By Zacks 2022-02-16
By Zacks 2022-03-14
By Zacks 2021-06-23